Comparison
DSIP vs. Ipamorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Growth
CAS no.
62568-57-4
170851-70-4
Molecular weight
848.81 g/mol
711.86 g/mol
Half-life
0.1 h
2 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluAib-His-D-2-Nal-D-Phe-Lys-NH2Mechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
4
of which in humans
1
3
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
1